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Addition of phorbol ester-activated, partially purified protein kinase C to membranes of human platelets 
had no effect on forskolin stimulation of the adenylate cyclase and increased stimulation by prostaglandin 
E, only at high GTP concentrations by preventing inhibition by GTP. Hormonal inhibition of the platelet 
adenylate cyclase by epinephrine was eliminated or largely impaired. At low GTP concentrations, epi- 
nephrine even caused a small increase in cyclase activity. The data suggest hat activated protein kinase C 
interferes with GTP- and hormone-induced adenylate cyclase inhibition probably by phosphorylating the 
inhibitory guanine nucleotide-binding regulatory component N,. 
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1. INTRODUCTION 
The adenylate cyclase of human platelet mem- 
branes is stimulated and inhibited, respectively, by 
the hormonal factors, prostaglandin El (PGEI) 
and epinephrine, acting via the stimulatory (N,) 
and inhibitory (Ni) guanine nucleotide-binding 
regulatory components [l]. We have recently 
reported that treatment of intact platelets with the 
tumor-promoting phorbol ester, 12-O-tetradeca- 
noylphorbol-13-acetate (TPA), largely affects 
adenylate cyclase regulation via the inhibitory 
guanine nucleotide site Ni 121. In membranes of 
TPA-pretreated platelets, basal and forskolin- 
stimulated activities were largely unaltered. Fur- 
thermore, adenylate cyclase stimulation via the 
stimulatory guanine nucleotide site N, by fluoride 
or the hormonal factor, PGE1, was basically un- 
changed. In contrast, GTP-induced inhibition of 
PGEI-stimulated activity and, most important, 
GTP-dependent epinephrine- and thrombin- 
induced inhibition of basal, PGEI- or forskolin- 
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stimulated activities were prevented or largely 
reduced in membrane of TPA-pretreated platelets. 
The data accumulated suggested that the observed 
effects of TPA are due to an activation of the 
Ca’+-activated, phospholipid-dependent protein 
kinase (protein kinase C) by the tumor-promoting 
phorbol ester [3]. 
To substantiate this suggestion, we studied 
whether addition of purified protein kinase C to 
membranes of human platelets causes similar 
changes in regulation of adenylate cyclase activity 
as observed in membranes of TPA-pretreated 
platelets. We report here that activated protein 
kinase C interferes with Ni-mediated adenylate 
cyclase inhibition in platelet membranes. 
2. MATERIALS AND METHODS 
TPA was kindly supplied by Dr E. Hecker, 
Heidelberg, and forskolin by Dr H. Metzger, 
Hoechst AG, Frankfurt. Epinephrine, PGEl and 
dl-propranolol were purchased from Sigma. Pro- 
tein kinase C was partially purified from chick 
oviduct as in [4] with a specific activity of more 
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than 300 mU/mg protein. One unit is defined as 
the enzyme activity which phosphorylates 1 prnol 
histone III-S per min at 30°C. Membranes of 
human platelets were prepared as in [5] with 5 mM 
EDTA present hroughout the membrane prepara- 
tion procedure. 
Adenylate cyclase activity was determined, if not 
otherwise indicated, in a reaction mixture contain- 
ing 50 PM [a-32P]ATP (about 0.3 &i/tube), 
5 mM MgC12, 100 PM CaC12, 50pM EDTA, 
50 PM EGTA, 1 mM dithiothreitol, 5 mM 
2-mercaptoethanol, 1 mM 3-isobutyl-l-methyl- 
xanthine, 5 mM creatine phosphate, 0.4 mg/ml 
creatine kinase and the additions indicated in 
50 mM triethanolamine-HCI, pH 7.4, in a total 
volume of 100~1. When the effect of TPA was 
studied, controls contained the same concentration 
of acetone as the TPA-containing tubes, which was 
maximally 0.2% (v/v). Platelet membranes (about 
10 pg protein per tube) were preincubated with the 
reaction mixture in the absence and presence of 
purified protein kinase C (2 mu/ml) as indicated 
for 10 min at 30°C. Thereafter, labelled ATP was 
added and the adenylate cyclase reaction was con- 
tinued for 10 min at 30°C. Termination of the 
reaction and isolation of cyclic AMP formed were 
carried out as in [6]. The time course and constant 
time experiments were performed in duplicate and 
triplicate, respectively, and were repeated at least 
twice with results comparable to those shown here. 
3. RESULTS 
In the presence of the stimulatory hormone, 
PGEl (lOpM), GTP has a biphasic effect on 
adenylate cyclase activity in human platelet mem- 
branes [2] (fig. 1). At low concentrations, up to 0.1 
or 0.3 PM, GTP increases stimulation of the en- 
zyme by PGEi, the activity of which is lo-15-fold 
above basal activity even without GTP added. At 
higher concentrations (2 0.3 PM), GTP reduces 
PGEi-stimulated activity. When purified protein 
kinase C (2 mU/ml) and TPA (0.4pM) were in- 
cluded in the preincubation mixture, there was no 
change in stimulated activity without GTP added. 
Furthermore, the increase in stimulation caused by 
GTP was very similar to that under control condi- 
tions. However, the inhibitory phase of GTP’s ac- 
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Fig.1. Modulation of GTP action on PGEr-stimulated 
human platelet adenylate cyclase by TPA-activated 
protein kinase C. Adenylate cyclase activity was 
determined in the absence (0) and presence (0) of TPA 
(0.4pM) plus protein kinase C (PKC; 2 mu/ml) at the 
indicated concentrations of GTP. PGEr (10pM) was 
always present. 
largely impaired or eliminated after pretreatment 
with protein kinase C plus TPA. TPA by itself, 
without protein kinase C, had no effect on platelet 
membrane adenylate cyclase activity (not shown). 
Forskolin (20 PM)-stimulated platelet adenylate 
cyclase activity was not affected by either TPA or 
protein kinase C or the combination of both agents 
(fig.2). In the presence of 1OrM GTP, the in- 
hibitory hormone, epinephrine (10 pM), reduced 
the forskolin-stimulated activity by about 50%. 
This GTP-dependent, hormone-induced inhibition 
was not affected by the addition of TPA (0.4 FM) 
alone. However, when protein kinase C (2 mu/ml) 
and TPA were combined, the epinephrine-induced 
inhibition was almost completely abolished, after a 
small lag phase of about 2 min. Addition of 
purified protein kinase C to platelet membranes 
without the activator was not sufficient to prevent 
epinephrine-induced inhibition. As shown in fig.3, 
with protein kinase C (2 ml-J/ml) present, 
epinephrine (10 PM) still reduced the forskolin- 
stimulated activity by about 30%. This inhibition 
by epinephrine was concentration-dependently im- 
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Fig.2. Influence of TPA and TPA-activated protein 
kinase C on forskolin-induced stimulation and 
epinephrine-induced inhibition of platelet adenylate 
cyclase. Cyclic AMP accumulation was studied in 
membranes of human platelets with 20 pM forskolin and 
1OpM GTP present in the absence (0, A , q ) and 
presence (0, A , n ) of 10pM epinephrine (Epi) for the 
indicated periods of time. The measurement was started 
by the addition of membranes. (0, l ) Control; (A , A) 
0.4 ,uM TPA; ( q , n ) TPA plus protein kinase C (PKC; 
2 mu/ml). 
paired by the addition of TPA, an activator of the 
protein kinase C [3]. Half-maximal inhibition of 
the inhibitory effect of epinephrine was observed 
at about 10 nM TPA. 
At low GTP concentrations, inhibition of 
platelet adenylate cyclase by epinephrine is re- 
duced. With 0.1 PM GTP present, maximal inhibi- 
tion of the forskolin-stimulated activity by 10/1M 
epinephrine was about 30% (fig.4). Addition of 
TPA (0.4 PM) plus protein kinase C (2 mu/ml) 
not only prevented the inhibition by epinephrine, 
but after treatment with these agents, epinephrine 
even caused a small increase in stimulated activity. 
This increase was 30-409’0 at 1 PM epinephrine 
and was not due to a possible action of epinephrine 
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Fig.3. Influence of TPA on protein kinase C-induced 
impairment of epinephrine-induced inhibition of platelet 
adenylate cyclase. Adenylate cyclase activity was 
determined with 20gM forskolin, 1OpM GTP and 
2 mu/ml protein kinase C (PKC) present in the absence 
(0) and presence (0) of 10pM epinephrine (Epi) at the 
indicated concentrations of TPA. 
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Fig.4. Reversal of epinephrine-induced inhibition of 
human platelet adenylate cyclase by activated protein 
kinase C. Adenylate cyclase activity was determined with 
20 PM forskolin, 10 PM dl-propranolol and 0.1 PM 
GTP present in the absence (0) and presence (0) of 
TPA (0.4 FM) L IS protein kinase C (PKC; 2 mu/ml) at 
the indicat d concentrations of epinephrine. 
25 
Volume 192, number 1 FEBS LETTERS November 1985 
at platelet ,8-adrenoceptors [l], since the ,&- 
adrenoceptor blocking agent, dl-propranolol 
(lOrM), was included in the assay. 
4. DISCUSSION 
The data reported here indicate that the addition 
of partially purified and activated protein kinase C 
to membranes of human platelets has no major ef- 
fect on forskolin stimulation of the platelet 
adenylate cyclase. Furthermore, stimulation of the 
platelet enzyme by the hormonal factor, PGEr, 
was apparently also unaffected by this treatment. 
These data suggest hat activated protein kinase C 
has no major effect on the adenylate cyclase 
catalytic moiety, which is apparently one or the site 
of action of forskolin [7]. Furthermore, the 
stimulatory signal transduction system to the 
adenylate cyclase is apparently also not affected, 
as shown with PGEr, which after interaction with 
specific receptors causes adenylate cyclase stimula- 
tion via the stimulatory guanine nucleotide- 
binding regulatory site N,. In contrast, inhibition 
of the platelet adenylate cyclase by GTP itself, as 
observed in the presence of PGEi, and by the hor- 
monal factor, epinephrine, was eliminated or 
largely impaired in platelet membranes treated 
with TPA-activated protein kinase C. Thus, the in- 
hibitory transduction system to the adenylate 
cyclase involving the Ni component is apparently 
inactivated by the activated kinase. These data are 
virtually identical to those reported before [2] in 
membranes of human platelets pretreated with 
TPA. It can, thus, be concluded that the observed 
effects of TPA [2] are due to an activated protein 
kinase C. 
Two more points have to be discussed. First, the 
target of protein kinase C-induced phosphoryla- 
tion, which is responsible for the effects reported 
here, is apparently the guanine nucleotide-binding, 
a-subunit of Ni, as shown by studies in intact and 
solubilized platelet membranes and with purified 
Ni and its subunits [8]. Thus, the sequence of 
events appears to be that TPA activates the soluble 
protein kinase C, which then associates with the 
membranes [3] and causes phosphorylation of the 
ai subunit. The phosphorylated Ni can apparently 
not be activated by GTP and inhibitory hormonal 
factors, which results in a loss of GTP-dependent 
26 
and hormone-induced adenylate cyclase inhibition. 
The second point is that after pretreatment with 
activated protein kinase C the ‘normally’ in- 
hibitory hormone, epinephrine, can even cause an 
increase in adenylate cyclase activity (fig.4). This 
increase was only observed at low GTP concentra- 
tions (0.1 PM), while at high concentrations of 
GTP (10 PM) the activated protein kinase C only 
impaired or abolished the epinephrine-induced in- 
hibition. Similar data have not been reported 
before with pertussis toxin (islet-activating protein) 
which inactivates Ni by ADP-ribosylating its LY- 
subunit [9], suggesting that the ADP-ribosylation 
and the phosphorylation of ai by pertussis toxin 
and protein kinase C, respectively, both func- 
tionally inactivate Ni but by quite distinct 
mechanisms and apparently with partially distinct 
consequences. Whatever the mechanism is by 
which treatment with activated protein kinase C 
can lead to an increase in adenylate cyclase activity 
by a normally inhibitory hormone, the data are 
reminiscent of those obtained in intact cells with 
hormones causing activation of protein kinase C 
apparently by stimulating the phosphoinositide 
metabolism. With some of these hormones, e.g., 
the chemotactic peptide, N-formylmethionylleu- 
cylphenylalanine, in leukocytes and cyr-adrenergic 
agonists in pinealocytes, it has been reported that 
these hormonal agents have no stimulatory effect 
on adenylate cyclase activity in membrane prepara- 
tions but can increase basal or stimulated cyclic 
AMP levels in intact cells [ 10,l 11. It is feasible that 
this increase in cyclic AMP levels is caused by a 
hormone receptor-mediated formation of diacyl- 
glycerol, causing activation of protein kinase C, 
which then phosphorylates and inactivates the in- 
hibitory guanine nucleotide-binding regulatory 
component Ni of the adenylate cyclase system. 
This suggested sequence of events has to be 
clarified by studies in intact cellular systems. 
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